Kingdomway(SZ:002626) Soochow Securities·2025-12-26 05:14Investment Rating - The report gives a "Buy" rating for the company, Jin Dawei (002626), marking the first coverage of the stock [1]. Core Views - Jin Dawei is a leading health supplement company in China with a comprehensive industry chain covering raw material supply, production, and brand operation. The company has a strong market position, particularly in coenzyme Q10, which has a global market share of 50-60% [12][59]. - The health supplement industry in China is expected to maintain a high single-digit growth rate from 2025 to 2027, driven by an aging population and new consumer trends. The online sales channel is becoming increasingly important, with e-commerce expected to account for over 50% of sales by 2024 [41][54]. - The company's revenue and net profit are projected to grow significantly, with net profits expected to reach 442.23 million yuan in 2025, reflecting a year-on-year growth of 29% [1][26]. Summary by Sections 1. Company Overview - Jin Dawei has established a full industry chain, including upstream raw materials like coenzyme Q10 and vitamins, and downstream brands such as Doctor's Best, which has become a significant player in the North American market [12][16]. - The company has a stable shareholding structure, with the largest shareholder holding 34.71% of the shares, ensuring strategic consistency [21][24]. 2. Health Supplement Industry - The health supplement market in China has grown from 70.135 billion yuan in 2010 to 232.339 billion yuan in 2024, with a CAGR of 8.93% [41]. - The aging population is a key driver for long-term demand in the health supplement sector, with the proportion of individuals aged 65 and above exceeding 14% in 2023 [42]. 3. Brand Development and Raw Material Contribution - Coenzyme Q10 is a leading product for Jin Dawei, with a strong market presence and expected growth in demand due to its health benefits [59]. - The company has diversified its brand portfolio, including products that cater to various health needs, and is expanding its presence in the domestic market through e-commerce channels [16][18]. 4. Financial Projections and Valuation - The company is projected to achieve a net profit of 442.23 million yuan in 2025, with an EPS of 0.73 yuan, indicating a favorable valuation compared to peers [1][26]. - The report highlights that the current P/E ratio is 28x for 2025, suggesting that the stock is undervalued relative to comparable companies [1].